Second cohort following patients entering a multidisciplinary care pathway for post-COVID syndromes (SyPoCo2)
Official title: Second Prospective Cohort of Patients Entering the Multidisciplinary Care Pathway for Post-Covid Syndromes - SyPoCo2 Cohort
Run by Hospices Civils de Lyon · NCT07356570 · Data updated 2026-11-12
This project will test whether linking long COVID patients' symptoms with blood immune and molecular markers can find biomarkers and possible treatment targets.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 2 sites (Pierre-Bénite and 1 other locations) |
| Status | Recruiting |
| Started | June 13, 2025 |
| Main results expected | June 2026 |
| Study ends | June 2026 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT07356570 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with documented SARS-CoV-2 infection who have persistent or complex post-COVID symptoms and are referred to the EPSILON pathway or the post-COVID rehabilitation unit, non-institutionalized, and expected to survive more than six months are ideal candidates.
✕Probably not a fit
People without confirmed SARS-CoV-2 infection, with uncontrolled comorbidities, who are pregnant or breastfeeding, under legal protection or deprived of liberty, not covered by the French national health insurance system, or institutionalized are not eligible and would not benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
SyPoCo2 is an observational cohort enrolling adults referred to specialized post-COVID care pathways in the Hospices Civils de Lyon system. Participants provide blood samples and detailed clinical information so researchers can correlate symptom patterns with immunological and molecular data. The goal is to identify prognostic biomarkers and signals that could point to therapeutic targets. Data will be analyzed to define clinical profiles and molecular signatures associated with persistent post-COVID symptoms.
Why it matters
Potential benefit: If successful, the work could produce blood-based markers that help predict who will have prolonged symptoms and suggest targets for future treatments.
How similar studies have gone: Previous observational cohorts have identified immune and molecular signals linked to long COVID but no universally validated prognostic biomarkers or approved targeted therapies have yet been established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Documented SARS-CoV-2 infection * Persistent or complex post-COVID symptoms lasting more than 4 weeks or more than 3 months * Patient referred to the EPSILON pathway or to the post-COVID rehabilitation unit * Age ≥ 18 years * Non-institutionalized * Expected survival greater than 6 months Exclusion Criteria: * Refusal to participate or to share data * Uncontrolled comorbidities * Pregnant or breastfeeding women * Persons under legal protection or deprived of liberty * Not affiliated with the French national health insurance system
Where it's running
-
Service Pneumologie aigue spécialisée et cancérologie thoracique
Pierre-Bénite, France Recruiting -
Hôpital Henry Gabrielle-HCL
Saint-Genis-Laval, France Recruiting
Study contacts
- Study coordinator: Sébastien Couraud, Pr
- Email: Sebastien.couraud@chu-lyon.fr
- Phone: 04 78 86 44 01
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Accelerated intermittent theta-burst stimulation for depression with post‑COVID‑19 condition
This will test whether two different schedules of intermittent theta-burst stimulation (accelerated TMS) reduce depressive symptoms and inflammation in adults aged 18–65 who have depressive disorder plus post‑COVID‑19 condition.
-
2-HOBA to reduce persistent immune activation in Long COVID with POTS
This trial will test whether 2‑HOBA, a compound that scavenges harmful IsoLG-adducts, can reduce immune activation in adults with Long COVID who have POTS.
-
Long COVID relief through learning mindfulness
This study will try an 8-week online recorded mindfulness program to see if it reduces stress and Long COVID symptoms in adults who continue their usual care.
-
Investigating dysfunctional breathing in patients with post COVID-19 condition
This study is trying to see how breathing problems affect people who are dealing with long-term symptoms after having COVID-19.
-
Evaluating Apabetalone for Long-COVID in Diabetes Patients
This study is testing if adding a new medication called Apabetalone to the diabetes drug dapagliflozin can help people with Type 2 Diabetes who are dealing with Long-COVID symptoms feel better.
-
Effects of exercise on heart and lung responses in post-COVID-19 patients
This study tests how exercise affects heart and lung responses in people who have had COVID-19, comparing those with ongoing symptoms to those without.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.